Advertisement

Topics

IBI: This is the moment Teva has feared

11:26 EDT 4 Oct 2017 | Globes

IBI analyst Steven Tepper says Mylan's generic Copaxone approval earlier than expected will hit cash flow as Teva tries to cut debt.

Original Article: IBI: This is the moment Teva has feared

NEXT ARTICLE

More From BioPortfolio on "IBI: This is the moment Teva has feared"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...